Cymabay Therapeu Probability of Future Stock Price Finishing Over 8.08

CBAYDelisted Stock  USD 11.83  0.27  2.34%   
Cymabay Therapeu's future price is the expected price of Cymabay Therapeu instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Cymabay Therapeu performance during a given time horizon utilizing its historical volatility. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
  
Please specify Cymabay Therapeu's target price for which you would like Cymabay Therapeu odds to be computed.

Cymabay Therapeu Target Price Odds to finish over 8.08

The tendency of Cymabay Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to stay above $ 8.08  in 90 days
 11.83 90 days 8.08 
about 92.88
Based on a normal probability distribution, the odds of Cymabay Therapeu to stay above $ 8.08  in 90 days from now is about 92.88 (This Cymabay Therapeu probability density function shows the probability of Cymabay Stock to fall within a particular range of prices over 90 days) . Probability of Cymabay Therapeu price to stay between $ 8.08  and its current price of $11.83 at the end of the 90-day period is about 88.01 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.61 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Cymabay Therapeu will likely underperform. Additionally Cymabay Therapeu has an alpha of 0.2013, implying that it can generate a 0.2 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Cymabay Therapeu Price Density   
       Price  

Predictive Modules for Cymabay Therapeu

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cymabay Therapeu. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
11.8311.8311.83
Details
Intrinsic
Valuation
LowRealHigh
9.139.1313.01
Details
Naive
Forecast
LowNextHigh
11.1711.1711.17
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
9.0310.6712.32
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Cymabay Therapeu. Your research has to be compared to or analyzed against Cymabay Therapeu's peers to derive any actionable benefits. When done correctly, Cymabay Therapeu's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Cymabay Therapeu.

Cymabay Therapeu Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Cymabay Therapeu is not an exception. The market had few large corrections towards the Cymabay Therapeu's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cymabay Therapeu, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cymabay Therapeu within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.20
β
Beta against Dow Jones1.61
σ
Overall volatility
1.20
Ir
Information ratio 0.05

Cymabay Therapeu Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cymabay Therapeu for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cymabay Therapeu can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Cymabay Therapeu is not yet fully synchronised with the market data
Cymabay Therapeu has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 31.07 M. Net Loss for the year was (105.37 M) with loss before overhead, payroll, taxes, and interest of (41.63 M).
Cymabay Therapeu currently holds about 153.42 M in cash with (72.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.81.
Over 99.0% of the company shares are held by institutions such as insurance companies

Cymabay Therapeu Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cymabay Stock often depends not only on the future outlook of the current and potential Cymabay Therapeu's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cymabay Therapeu's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding106.2 M
Cash And Short Term Investments394.3 M

Cymabay Therapeu Technical Analysis

Cymabay Therapeu's future price can be derived by breaking down and analyzing its technical indicators over time. Cymabay Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Cymabay Therapeu. In general, you should focus on analyzing Cymabay Stock price patterns and their correlations with different microeconomic environments and drivers.

Cymabay Therapeu Predictive Forecast Models

Cymabay Therapeu's time-series forecasting models is one of many Cymabay Therapeu's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Cymabay Therapeu's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Cymabay Therapeu

Checking the ongoing alerts about Cymabay Therapeu for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Cymabay Therapeu help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Cymabay Therapeu is not yet fully synchronised with the market data
Cymabay Therapeu has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 31.07 M. Net Loss for the year was (105.37 M) with loss before overhead, payroll, taxes, and interest of (41.63 M).
Cymabay Therapeu currently holds about 153.42 M in cash with (72.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.81.
Over 99.0% of the company shares are held by institutions such as insurance companies
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Other Consideration for investing in Cymabay Stock

If you are still planning to invest in Cymabay Therapeu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cymabay Therapeu's history and understand the potential risks before investing.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Bonds Directory
Find actively traded corporate debentures issued by US companies
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
CEOs Directory
Screen CEOs from public companies around the world
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals